LAS VEGAS, June 29 /PRNewswire-FirstCall/ -- PhytoLabs Inc. today announced that its subsidiary, Phytolab Solutions Inc., has been notified by their sub-licensee Nordic Immotech Trading (NIT) that the Danish firm has signed a deal to distribute Phytolab Solutions’ new immuno-stimulatory product in Turkey. The Danish life science firm expects sales to commence in early fall.
“Completion of this deal demonstrates the value of the sub-license agreement with Nordic Immotech Trading,” said Phytolab Solutions COO David Wood. “Having them now developing sales in new markets outside of Europe opens those markets, creates revenue, and frees us up to focus on our core North American markets,” said Wood. NIT expects to commence sales in the new territory in the early fall.
Ongoing negotiations continue for similar sub-license agreements in other European countries as well as non-European countries. Several of these negotiations are now in advanced stages and further announcements are expected in the near future.
About PhytoLabs Inc.
PhytoLabs Inc. (“PYTL”) is a life science company focused on the global commercialization of unique, patented and scientifically proven natural-source health products that allow a proactive health management approach by delivering the highest levels of effectiveness, safety, and prevention. Further information on PhytoLabs Inc. is available at http://www.phytolabsinc.com.
PhytoLabs’ new, patented extract, developed by leading research scientists at the National Center for Natural Products Research (NCNPR) at the University of Mississippi, "... is one of the most promising projects our Center has produced in recent years, including its intellectual property,” says Dr. Walter G. Chambliss, Director of Technology Management at the University of Mississippi. “Our research has shown that this extract is the most powerful, natural immune-stimulatory dietary supplement discovered to date with respect to macrophage activation,” says Dr. David Pasco, Assistant Director at NCNPR. The results of this research were published in Planta Medica (Pugh et al, 2001 67(8): 737-742).
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products or actions in development are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results.
PhytoLabs Inc.
CONTACT: Anthony Carl Jurak of PhytoLabs Inc., +1-720-914-9688
